change the trajectory of health for humanity.
HC-1119
• Indication:castration-resistant prostate cancer (CRPC)• Current Stage:Global phase III• Information on China Drug Trials Registration and Publicity Platform（need to input “HC-1119” and search）:• Information on ClinicalTrials.gov:HP501
• HP501hyperuricemia (with gout or with no symptom)• Current Stage:Phase II in China• Information on China Drug Trials Registration and Publicity Platform (need to input "HP501”and search):
We are respectful to doctors who are devoted to medical advancement and sincerely look forward to communicating and collaborating with medical experts in various fields to create a better medical environment.
Research and Development
Hinova is proud of its successfully partnering with external organizations that have highly regarded international reputation and share in our purpose to deliver life-changing medicines.
We are expecting to work together with more excellent partners from different fields.
If you have any intention to collaborate with us, please contact with our BD department.
With the support of the investors, our pipelines have been advanced very quickly. We are expecting to work together with the investors to bring promising innovative drugs to the market.
Investors
One of our ways to make a better world is to develop innovative, effective drugs and improve the lives. We're committed to giving back to both the patient communities we serve and the community in which we live.
Postal Code: 610041
Headquarters address: No. 2 and No. 3, Floor 4, Building 1, Rongyao Building, Keyuan South Road 5, High-tech Zone, Chengdu City, Sichuan Province
关注公众号
